These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 33669326)

  • 1. Tumor Type Agnostic Therapy Carrying BRAF Mutation: Case Reports and Review of Literature.
    Bernocchi O; Sirico M; Corona SP; Strina C; Milani M; Cappelletti MR; Ferrero G; Ziglioli N; Cervoni V; Macchiavelli A; Roviello G; Generali D
    Pharmaceuticals (Basel); 2021 Feb; 14(2):. PubMed ID: 33669326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dabrafenib and trametinib administration in patients with
    Shimoi T; Sunami K; Tahara M; Nishiwaki S; Tanaka S; Baba E; Kanai M; Kinoshita I; Shirota H; Hayashi H; Nishida N; Kubo T; Mamesaya N; Ando Y; Okita N; Shibata T; Nakamura K; Yamamoto N
    EClinicalMedicine; 2024 Mar; 69():102447. PubMed ID: 38333370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Redifferentiation of BRAF V600E-Mutated Radioiodine Refractory Metastatic Papillary Thyroid Cancer After Treatment With Dabrafenib and Trametinib.
    Jafri S; Yaqub A
    Cureus; 2021 Aug; 13(8):e17488. PubMed ID: 34595070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expanding the Benefit: Dabrafenib/Trametinib as Tissue-Agnostic Therapy for
    Gouda MA; Subbiah V
    Am Soc Clin Oncol Educ Book; 2023 May; 43():e404770. PubMed ID: 37159870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting oncogenic Raf protein-serine/threonine kinases in human cancers.
    Roskoski R
    Pharmacol Res; 2018 Sep; 135():239-258. PubMed ID: 30118796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trametinib: a MEK inhibitor for management of metastatic melanoma.
    Lugowska I; Koseła-Paterczyk H; Kozak K; Rutkowski P
    Onco Targets Ther; 2015; 8():2251-9. PubMed ID: 26347206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impressive response to dual
    Lavingia V; Fakih M
    J Gastrointest Oncol; 2016 Dec; 7(6):E98-E102. PubMed ID: 28078132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Case report: Dual dabrafenib and trametinib therapy for treating BRAF V600E mutated lung adenocarcinoma with BRCA2 germline mutation post multiline progression.
    Zhang H; Cong X; Yin J; Chen C; Liu Z
    Front Oncol; 2024; 14():1387388. PubMed ID: 38715777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting BRAF mutations in non-small cell lung cancer.
    O'Leary CG; Andelkovic V; Ladwa R; Pavlakis N; Zhou C; Hirsch F; Richard D; O'Byrne K
    Transl Lung Cancer Res; 2019 Dec; 8(6):1119-1124. PubMed ID: 32010589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adverse Event Management in Patients with
    Chalmers A; Cannon L; Akerley W
    Oncologist; 2019 Jul; 24(7):963-972. PubMed ID: 30598499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Indirect treatment comparison of dabrafenib plus trametinib versus vemurafenib plus cobimetinib in previously untreated metastatic melanoma patients.
    Daud A; Gill J; Kamra S; Chen L; Ahuja A
    J Hematol Oncol; 2017 Jan; 10(1):3. PubMed ID: 28052762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Papillary Thyroid Cancer Differentiating Into Anaplastic Carcinoma With Near-Complete Response to Targeted Dabrafenib/Trametinib Combination Therapy.
    Kulkarni P; Hall J; Wang L; Henderson S
    Cureus; 2021 Dec; 13(12):e20693. PubMed ID: 35106230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.
    Joshi M; Rice SJ; Liu X; Miller B; Belani CP
    PLoS One; 2015; 10(2):e0118210. PubMed ID: 25706985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
    Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
    Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dramatic response to dabrafenib and trametinib combination in a BRAF V600E-mutated cholangiocarcinoma: implementation of a molecular tumour board and next-generation sequencing for personalized medicine.
    Loaiza-Bonilla A; Clayton E; Furth E; O'Hara M; Morrissette J
    Ecancermedicalscience; 2014; 8():479. PubMed ID: 25435907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer.
    Subbiah V; Kreitman RJ; Wainberg ZA; Cho JY; Schellens JHM; Soria JC; Wen PY; Zielinski C; Cabanillas ME; Urbanowitz G; Mookerjee B; Wang D; Rangwala F; Keam B
    J Clin Oncol; 2018 Jan; 36(1):7-13. PubMed ID: 29072975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRAF mutant non-small cell lung cancer and treatment with BRAF inhibitors.
    Sánchez-Torres JM; Viteri S; Molina MA; Rosell R
    Transl Lung Cancer Res; 2013 Jun; 2(3):244-50. PubMed ID: 25806238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mitogen-Activated Protein Kinase Pathway Inhibition for Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer: An Evolving Protocol.
    Iravani A; Solomon B; Pattison DA; Jackson P; Ravi Kumar A; Kong G; Hofman MS; Akhurst T; Hicks RJ
    Thyroid; 2019 Nov; 29(11):1634-1645. PubMed ID: 31637953
    [No Abstract]   [Full Text] [Related]  

  • 19. Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAF
    Schreuer M; Jansen Y; Planken S; Chevolet I; Seremet T; Kruse V; Neyns B
    Lancet Oncol; 2017 Apr; 18(4):464-472. PubMed ID: 28268064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dabrafenib plus Trametinib: a Review in Advanced Melanoma with a BRAF (V600) Mutation.
    Dhillon S
    Target Oncol; 2016 Jun; 11(3):417-28. PubMed ID: 27246822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.